Peritransplantation Use of Ruxolitinib in Myelofibrosis
Copyright policy )Peritransplantation Use of Ruxolitinib in Myelofibrosis
Ruxolitinib is an oral JAK1/2 inhibitor that is approved for use in patients with intermediate and high-risk myelofibrosis (MF) based on its proven spleen and symptom burden reduction. Its impact on hematopoietic stem cell transplantation (HSCT) outcomes is largely unknown, however. A significant number of patients proceeding to HSCT have been treated with ruxolitinib, and the specifics of its peritransplantation use vary widely in the published literature. Here we review the currently published data and experience to guide management of patients with MF on ruxolitinib proceeding to HSCT.
- Icahn School of Medicine at Mount Sinai United States
- Tisch Cancer Institute United States
Pyrimidines, Primary Myelofibrosis, Nitriles, Hematopoietic Stem Cell Transplantation, Humans, Pyrazoles, Protein Kinase Inhibitors
Pyrimidines, Primary Myelofibrosis, Nitriles, Hematopoietic Stem Cell Transplantation, Humans, Pyrazoles, Protein Kinase Inhibitors
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).6 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!